Author: Kaye

In Dec 2022, Xenoview™, a hyperpolarized contrast agent prepared from a proprietary Xenon 129Xe Gas Blend, received FDA approval

In Dec 2022, the FDA approved BRIUMVI™, a chimeric monoclonal antibody (mAb) labelled for the treatment of RMS

Lenacapavir (Sunleca®), a first-in-class long-acting HIV-1 capsid function inhibitor, was approved by the FDA in December 2022

In Dec 2022, the US Food and Drug Administration (FDA) approved MediWound’s biologic license application (BLA) for anacaulase-bcdb (NexoBrid®)

Disease Burden and Clinical Landscape Hepatorenal syndrome (HRS) is an extreme manifestation of progressive kidney function deterioration in patients with advanced liver disease. This is most common in those with advanced cirrhosis and ascites.1 HRS is further subdivided into several types that are generally differentiated by disease course i.e. HRS Type 1 (HRS-1), known more recently as HRS-acute kidney injury (HRS-AKI), or HRS Type 2 (HRS-2), which is further divided into HRS-acute kidney disease (HRS-AKD) and HRS-chronic kidney disease (HRS-CKD).2,3  HRS-1 or HRS-AKI is characterized by an abrupt deterioration of renal function whereby serum creatinine doubles or rises by at least 0.3…

The US FDA granted regulatory approval to Gadopiclenol (Elucirem™), a new macrocyclic GBCA for use in adults and children aged 2 years and older, for contrast-enhanced MRI.

On 22 Sep 2022, the US FDA approved Omlonti® 0.002% eye drops for the reduction of elevated intraocular pressure. Read more

Risdiplam is the only disease-modifying therapy granted local market authorisation by HSA. Read about how it is used as a treatment for SMA

Belimumab is a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator. Know more about its drug profile

Pralsetinib is a RET receptor tyrosine kinase inhibitor used to treat metastatic RET-driven non-small cell lung cancer. Learn more